麻豆视频

Global Blood Collection Market Trends and Insights

Growing Prevalence of Chronic Diseases

Chronic disorders now affect 76.4% of US adults, and incidence among younger cohorts is climbing, pushing routine venous and capillary testing demand upward. Healthcare providers are scaling automated analyzers and decentralized sampling kits to manage rising specimen volumes without proportionally increasing headcount. Value-based care contracts tie reimbursement to timely monitoring, prompting hospitals to embed point-of-care (POC) coagulation and HbA1c panels inside primary-care clinics. Device makers respond by miniaturizing tubes pre-filled with optimized anticoagulants that preserve biomarkers for extended transport windows. These shifts collectively reinforce sustained revenue visibility for the blood collection market.

Rising Incidence of Trauma and Accidents

Urbanization correlates with higher trauma presentations that require immediate type-and-screen and coagulation work-ups. Level-I trauma centers are outfitting emergency bays with cartridge-based POC analyzers fed by 2 mL arterial draws, delivering results inside 3 minutes. The strategy reduces door-to-intervention time and improves survival metrics, nudging regional hospitals to replicate the model. Suppliers have introduced vacuum-assisted winged infusion sets with integrated flash-visibility to shorten first-stick time and minimize redraws under chaotic conditions. Emerging-market facilities are leapfrogging to these safety-optimized kits as donor agencies underwrite procurement.

Increasing Volume of Surgical Procedures

Elective and cancer-related surgeries rebounded in 2024, driving a 7% rise in blood sample throughput at leading academic medical centers. Higher median BMI among surgical candidates raises the probability of complex draws, fostering adoption of ultrasound-guided collection carts that locate deep veins swiftly. Minimally invasive techniques demand tighter peri-operative hemoglobin tracking, so operating suites now integrate inline sampling lines that funnel micro-volumes directly to blood gas analyzers. Collectively, these practices lift per-patient draw frequency, bolstering the blood collection market.

Expansion of Diagnostic and Point-of-Care Testing Infrastructure

Seventy-seven percent of hospitals ran POC blood-gas panels in 2024, reflecting a pivotal shift toward near-patient analytics. Pharmacy chains follow suit, piloting capillary-based lipid and COVID-19 antibody screens that need just six drops of blood using BD MiniDraw devices. Remote communities exploit mobile vans outfitted with battery-powered centrifuges, closing diagnostic gaps without building full labs. This democratization of testing scales demand for lightweight collection kits compatible with rugged environments, fuelling the blood collection market over the forecast horizon.

Risk of Blood-Borne Infections and Contamination

In 2025 the FDA issued updated hepatitis-B screening guidance that tightens performance criteria for donor testing platforms, raising compliance costs for collection centers. Facilities adopt double-sterility barriers and prefabricated closed-loop collection systems to mitigate contamination, but these safeguards elevate per-unit expense. Laboratories in infrastructure-poor regions struggle to fund such upgrades, deferring purchases and dampening near-term demand. Continuous surveillance for emerging pathogens maintains the pressure to upgrade devices, yet reimbursement schemes seldom offset added overhead, tempering the blood collection market鈥檚 expansion rate.

Needlestick Injuries and Associated Liability Costs

Hospital staff still sustain an estimated 385,000 needlestick incidents annually despite widespread safety devices, with 27.3% occurring even when protective features exist. Legal settlements and post-exposure prophylaxis inflate total cost per incident, steering procurement toward premium retractable or shielded needles. Asia-Pacific hospitals face unique challenges as insulin pen needles account for 20% of syringe injuries, prompting bulk conversion to safety-engineered pen sets. Although these transitions spur unit revenue growth, resistance from budget-constrained facilities can slow overall market uptake.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Segment Analysis

By Product: Tubes Drive Specialized Testing Growth

Needles and syringes accounted for 38.12% of 2025 revenue, underscoring their widespread use for venous access across various care settings. Tubes, however, constitute the fastest-advancing niche, set to log a 7.29% CAGR through 2031 as clinicians demand additive-coded vacutainers tailored for genetics, proteomics, and oncology panels. This trajectory highlights how assay sophistication reconfigures consumable mix within the blood collection market.

Demand for safety needles rises steadily thanks to OSHA standards, yet premium pricing moderates adoption speed in low-margin outpatient labs. Capillary lancets are gaining favor in retail clinics, where fingertip sampling is sufficient for metabolic and infectious disease screens. BD MiniDraw exemplifies capillary innovation, matching venous-draw accuracy with six-drop volumes, broadening consumer access. Blood bags maintain stable hospital demand for transfusion services, although synthetic substitutes and optimized inventory systems are curbing volume growth. Emerging robotic and needle-free products, currently a small slice, could capture an outsized share post-2030 as clinical validation accumulates.

By Collection Method: Automation Gains Despite Manual Dominance

Manual draws retained a 55.05% share in 2025, reflecting the entrenched nature of these skills and their minimal capital requirements, especially in community hospitals and mobile drives. Yet the automated cohort will expand at an 8.43% CAGR, propelled by phlebotomist shortages projected at 19,600 US openings per year. Institutions trial autonomous robots like Vitestro鈥檚 system, achieving 95% first-stick success and standardizing specimen quality.

High-volume outpatient labs justify robotics through throughput and reduced redraw costs, whereas critical-access hospitals still rely on manual versatility for challenging anatomies. AI-guided ultrasound probes integrate seamlessly into carts, reducing the average collection time to 90 seconds and minimizing patient discomfort. Capital expenditure remains a barrier; nonetheless, leasing models and productivity incentives are narrowing the affordability gap, sustaining the blood collection market鈥檚 automation pivot.

By Application: Diagnostics Dominate While Therapeutics Accelerate

Diagnostics captured 68.02% of 2025 turnover as chronic disease monitoring and preventive screens became routine in primary care. The inclusion of molecular assays in standard check-ups increases the per-test yield, reinforcing the centrality of diagnostics to the blood collection market size.

Therapeutic and transfusion-oriented draws are expected to increase at a faster 7.08% CAGR through 2031, driven by cell-therapy manufacturing and clinical trials for laboratory-grown red blood cells. Specialized apheresis kits and leukoreduction filters support this vertical, with RESTORE-trial milestones expected to stimulate additional demand. Laboratories expand specimen banking for personalized oncology, driving uptake of cryo-preservation tubes and RNA-stabilizing media. While regenerative medicine remains nascent, each incremental trial inflates the value of high-integrity collection products.

By End User: Point-of-Care Settings Surge Ahead

Hospitals and reference labs owned 53.78% of sales in 2025, leveraging integrated workflows and group purchasing power. Their centralized models facilitate the rapid adoption of next-generation safety consumables and automation, keeping them at the forefront of customers within the blood collection devices industry.

Point-of-care and home-care venues, however, will post an 8.21% CAGR, energized by consumer demand for convenience and telemedicine adoption. Pharmacy chains embed MiniDraw bays staffed by general nurses, enabling after-work lipid-panel checks with no venipuncture training. Mobile nursing fleets carry capillary kits to rural homes, closing equity gaps and expanding the total addressable market for blood collection. Blood banks maintain their strategic relevance for transfusion support, but optimization software now curbs wastage, tempering the volume growth. Research institutes and pharmaceutical sponsors contribute to a niche demand for protocol-specific kits that preserve novel biomarkers.

Geography Analysis

North America preserved 42.10% of 2025 revenue, buoyed by stringent OSHA compliance and high per-capita test utilization. Hospitals invest in robotic phlebotomy pilots and transition to fully closed systems to meet tightening donor-screening guidelines that favor high-throughput, error-proof devices. Growth remains moderate given the region鈥檚 installed base, yet replacement cycles and tech refreshes underpin predictable recurring sales.

Europe follows closely, guided by the 2024 EU Regulation on substances of human origin, which harmonizes safety standards across member states and encourages cross-border sharing of blood products. National health systems allocate modernization funds to vacuum-assisted safety tubes and barcode traceability, underpinning steady expansion. Pilot deployments of AI-enabled vein-finders in Germany and the Netherlands illustrate how clinical performance benchmarks catalyze procurement decisions, supporting revenue uplift across Western Europe.

Asia-Pacific is set to deliver the fastest 6.19% CAGR to 2031, drawing on healthcare infrastructure upgrades and policy initiatives like Australia鈥檚 Plasma Pathway that add 95,000 donations annually. China鈥檚 hospital expansion plans integrate fully automated sample-processing lines, magnifying demand for compatible closed-system consumables. India鈥檚 telehealth surge spurs rural adoption of capillary-based lipid and glucose testing, stretching distribution networks and providing fresh volume streams for the blood collection market. Though Middle East & Africa and South America trail in spending power, targeted investments in tertiary centers and trauma facilities signal rising opportunities, especially for safety-engineered needles that satisfy WHO injury-prevention guidelines.

Regulatory Landscape

Blood collection devices are governed by medical-device controls alongside blood and biologics requirements, which tend to steer manufacturers toward safety-engineered, traceable, and contamination-resistant designs. In the United States, FDA device classification covers capillary blood collection tubes under 21 CFR 864.6150 as Class I (general controls) and exempts them from premarket notification (as of April 2026). FDA guidance for blood collection, processing, and storage systems was refreshed via an October 2024 draft, with updated recommendations issued in June 2026, reinforcing expectations for system-level performance, labeling, and process controls.

In Europe, the EU MDR/IVDR transition continues to shape conformity assessment pathways, with Medical Device Coordination Group (MDCG) guidance updates across 2024-2025. This includes March 2025 updates to IVD classification guidance and January 2025 templates supporting IVDR preliminary assessments. Standards add another compliance anchor for suppliers active across regions, with ISO 23908:2024 (published December 2024) specifying sharps injury protection requirements relevant to blood collection, and ongoing standardization work in advanced consumables such as apheresis blood bag systems (ISO/DIS 3826-4) progressing through 2026, including the close of DIS voting on May 5, 2026.

Market Opportunities and Future Outlook

Clinical validation and regulatory clearances are widening the addressable market for automated and decentralized collection workflows, especially where staffing constraints and pre-analytical error reduction are procurement priorities. In April 2026, Vitestro published multicenter ADOPT trial results in Clinical Chemistry, reporting a 94.5% first-stick success rate for its Aletta autonomous robotic phlebotomy device. That evidence supports broader hospital and outpatient lab evaluation of robotics as a repeatable, standardized front-end to diagnostics. At the same time, FDA device pathways continue to support commercial scaling of capillary platforms, and in April 2026 BD received FDA 510(k) clearance (K252378) for the BD MiniDraw Capillary Blood Collection System, strengthening a retail and point-of-care operating model built around small-volume collection to extend testing access beyond traditional phlebotomy stations.

A second opportunity track is reworking the pre-analytical supply chain for ambient shipping and stabilization to enable remote and decentralized sampling. In April 2026, Covaris launched truCOLLECT, an FDA Class I-listed capillary blood collection device that integrates on-device stabilization and ambient shipping for DNA extraction, creating whitespace for kit vendors and diagnostics partners to bundle collection, stabilization chemistry, and logistics into a single workflow. Product registries also point to continued innovation in needle-free blood draw, including January 2026 updates to FDA GUDID listings for Venocare's Navi needle-free blood collection device designed to integrate with peripheral IV catheters, aligning with hospital goals to reduce needlestick risk and streamline repeat draws from existing access.